Research Topics
Genomes and Genes
| Liewei WangSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studiesThomas C Wood
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Biol Chem 281:7364-73. 2006..These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans...
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expressionLiang Li
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 68:7050-8. 2008..Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues...- Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyNifang Niu
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
BMC Cancer 12:422. 2012.... - FKBP51 regulation of AKT/protein kinase B phosphorylationLiewei Wang
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, MN, USA
Curr Opin Pharmacol 11:360-4. 2011..In this review, we will focus on the function of FKBP51 as a scaffolding protein in the regulation of AKT activation and, in turn, its role in tumorigenesis and response to chemotherapy... - Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directionsL Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Oncogene 25:1629-38. 2006.... - Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomicsLiewei Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
J Steroid Biochem Mol Biol 107:88-99. 2007..In aggregate, these results provide a basis for study of the possible role in human disease of common genetic variation in HSD3B1 and HSD3B2... 
Pharmacogenomics: a systems approachLiewei Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
Wiley Interdiscip Rev Syst Biol Med 2:3-22. 2010....- Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomicsLiewei Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Clin Cancer Res 14:3503-13. 2008..Genetic variation in proteasome subunits could influence both proteasome function and response to drug therapy... - Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitorsLiewei Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 70:319-28. 2010..Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors... - Human aromatase: gene resequencing and functional genomicsCynthia X Ma
Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Cancer Res 65:11071-82. 2005..These observations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiology of estrogen-dependent disease... - Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomicsYuan Ji
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
J Neurochem 95:1766-76. 2005..These observations raise the possibility of inherited variation in the ability to form epinephrine from norepinephrine as a result of variant PNMT polymorphisms and haplotypes... - Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomicsNifang Niu
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
J Clin Endocrinol Metab 94:3072-84. 2009..There are large variations in both physiological and therapeutic response to glucocorticoids. Multiple previous studies suggested that genetic polymorphisms in GRalpha (NR3C1) might play an important role... - Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomicsPinar Aksoy
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 19:567-76. 2009..One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3. Very little is known with regard to the pharmacogenomics of this family of enzymes... - Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersLiang Li
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
PLoS ONE 4:e7765. 2009.... - Gene set analysis of purine and pyrimidine antimetabolites cancer therapiesBrooke L Fridley
Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 21:701-12. 2011..Application of such methods to pharmacogenomic studies may enable the detection of more subtle effects of multiple genes in the same pathway that may be missed by assessing each gene individually... - Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formationLiewei Wang
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Proc Natl Acad Sci U S A 102:9394-9. 2005..The results of these experiments provide insight into a unique pharmacogenetic mechanism by which common polymorphisms affect TPMT protein function and, as a result, therapeutic response to thiopurine drugs... - Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancerLiang Li
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 22:105-16. 2012.... - Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomicsOreste E Salavaggione
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 15:801-15. 2005..These studies indicate that a common mechanism responsible for alterations in the activity of variant TPMT allozymes involves alteration in the level of enzyme protein due, at least in part, to accelerated degradation... - Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapyXiang Lin Tan
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Clin Cancer Res 17:5801-11. 2011.... - Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screenTse Yu Wu
Division of Clinical Pharmacology, Department of Pharmacology and Experimental Therapeutics, Rochester, MN 55905, USA
Int Immunopharmacol 11:1057-64. 2011..These studies have identified novel candidate genes that may contribute to variation in response to MPA therapy and, as a result, may help make it possible to move toward more highly individualized MPA-based immunosuppressive therapy... - FKBP51 affects cancer cell response to chemotherapy by negatively regulating AktHuadong Pei
Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Cancer Cell 16:259-66. 2009..Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy... - Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model systemLiewei Wang
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA
Biochem Biophys Res Commun 325:426-33. 2004..The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence... - FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorderKatarzyna A Ellsworth
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 23:156-66. 2013.... - Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogeneticsOreste E Salavaggione
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
Pharmacogenetics 12:713-24. 2002..These observations represent a step towards the application of pharmacogenetic and pharmacogenomic principles to companion animal drug therapy... - Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicityFang Li
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Drug Metab Dispos 38:2329-38. 2010..4 × 10(-10), R = -0.376). The thiopurine cellular circulation and genetic polymorphisms for genes encoding the proteins involved should be incorporated into future studies of thiopurine drug therapy and effect... - Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell linesNifang Niu
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
Genome Res 20:1482-92. 2010..Studies performed with LCLs can help to identify novel biomarkers that might contribute to variation in response to radiation therapy and enhance our understanding of mechanisms underlying that variation... - Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitorsJames N Ingle
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 28:4674-82. 2010.... - Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approachKrishna R Kalari
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
BMC Genomics 11:357. 2010..In the present study, we set out to test the hypothesis that variation in copy number might contribute to variation in cytidine analogue response phenotypes... - Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGGRyan Abo
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
PLoS ONE 7:e43301. 2012..Our proposed GS-eQTL method effectively addresses the multiple testing limitations in eQTL studies and provides biological context for SNP-expression associations... - Use of the gamma method for self-contained gene-set analysis of SNP dataJoanna M Biernacka
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Eur J Hum Genet 20:565-71. 2012..We also applied all of the considered GSA methods to data from a pharmacogenomic study of cisplatin, and obtained evidence suggesting that the glutathione metabolism GS is associated with cisplatin drug response... - A Bayesian integrative genomic model for pathway analysis of complex traitsBrooke L Fridley
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
Genet Epidemiol 36:352-9. 2012..Further research is required to extend and modify this integrative modeling framework to increase computational efficiency to best capitalize on the wealth of information available across multiple genomic data types... - A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicityBrooke L Fridley
Department of Health Sciences Research, Harwick 766, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Stat Med 28:2709-22. 2009.... - FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancerJunmei Hou
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
PLoS ONE 7:e36252. 2012..These results provide evidence in support of future clinical trials designed to tailor therapy based on our observations... - Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradationLiewei Wang
Departments of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
Pharmacogenetics 13:555-64. 2003..Therefore, chaperone proteins play an important mechanistic role in this clinically significant example of pharmacogenetic variation in drug metabolism... - MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sitesHuadong Pei
Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
Nature 470:124-8. 2011..Thus, we propose that a pathway involving γH2AX-MDC1-MMSET regulates the induction of H4K20 methylation on histones around DSBs, which, in turn, facilitates 53BP1 recruitment... - Testing whether genetic variation explains correlation of quantitative measures of gene expression, and application to genetic network analysisZhaoxia Yu
Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
Stat Med 27:3847-67. 2008..These methods can be used to assist the interpretation of regulation of gene expression and the construction of gene regulatory networks... - Pharmacogenomics: bench to bedsideRichard Weinshilboum
Mayo Medical School Mayo Graduate School, Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, Minnesota 55905, USA
Nat Rev Drug Discov 3:739-48. 2004.... - Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5'-flanking region single nucleotide polymorphism (SNP)Liewei Wang
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
Biochem Pharmacol 64:699-710. 2002..These results represent an additional step in the definition of molecular genetic mechanisms involved in the regulation of this important autacoid-metabolizing enzyme in humans... - Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expressionMohan Liu
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Breast Cancer Res 14:R41. 2012..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects... - Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphismsYuan Ji
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 68:5997-6005. 2008.... - Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradationFang Li
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Mayo Medical School, Rochester, Minnesota 55905, USA
Pharmacogenet Genomics 18:1083-94. 2008..It also forms aggresomes, suggesting a possible dynamic balance between degradation and aggregation. We set out to identify genes encoding proteins participating in these processes... - Pharmacogenomics: candidate gene identification, functional validation and mechanismsLiewei Wang
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School Mayo Clinic, Rochester, MN 55905, USA
Hum Mol Genet 17:R174-9. 2008.... - Candidate-gene association studies with pedigree data: controlling for environmental covariatesS L Slager
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905 USA
Genet Epidemiol 24:273-83. 2003..We also find GEE to fail at least 5% of the time for each simulation configuration; at times, the failure rate reaches above 80%. In summary, our robust method may be the only current regression analysis method available for MCC data... - Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapyYafei Li
Department of Health Sciences Research, Rochester, Minnesota, USA
Clin Cancer Res 17:3830-40. 2011.... - Localization of association signal from risk and protective variants in sequencing studiesAbra Brisbin
Department of Health Sciences Research, Mayo Clinic Rochester, MN, USA
Front Genet 3:173. 2012..The application of the sliding-window test procedure detected an association in a sub-region spanning an exon and two introns, when rare and common variants were analyzed together... - Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantityRichard Weinshilboum
Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School-Mayo Clinic-Mayo Foundation, Rochester, MN 55905, USA
Clin Pharmacol Ther 75:253-8. 2004 - Pharmacogenetics and pharmacogenomics: development, science, and translationRichard M Weinshilboum
Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School Mayo Foundation, Rochester, Minnesota 55905, USA
Annu Rev Genomics Hum Genet 7:223-45. 2006..However, significant challenges remain to be overcome if pharmacogenetics-pharmacogenomics is to achieve its full potential as a major medical application of genomic science... - Sumoylation of MDC1 is important for proper DNA damage responseKuntian Luo
Key Laboratory of Arrhythmia, Ministry of Education, East Hospital, Tongji University School of Medicine, Shanghai, China
EMBO J 31:3008-19. 2012..These results reveal the intricate dynamics governing the assembly and disassembly of DNA damage factors at sites of DNA damage for prompt response to DNA damage... - Role of HPC2/ELAC2 in hereditary prostate cancerL Wang
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Cancer Res 61:6494-9. 2001..Cumulatively, these results suggest that alterations within the HPC2/ELAC2 gene play a limited role in genetic susceptibility to HPC... - The APC E1317Q variant in adenomatous polyps and colorectal cancersD Hahnloser
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Epidemiol Biomarkers Prev 12:1023-8. 2003..These results underscore the importance of carefully defining the controls to be used in comparisons of allele frequencies... - Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cellsH Huang
Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer Res 59:2981-8. 1999..Our data demonstrate that the histone hyperacetylation signaling pathway is activated during NaBu-mediated differentiation of PC-3 cells, and the new gene, CPA3, is involved in this pathway... - Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cellsX Wang
George Whipple Laboratory for Cancer Research, Department of Urology, University of Rochester, Rochester, New York 14642, USA
J Biol Chem 276:40417-23. 2001..Together, our data demonstrate that ARA267-alpha is a new AR coregulator containing the SET domain with an exceptionally large molecular mass that can enhance AR transactivation in prostate cancer cells...
Research Grants
- Pharmacogenomics and Mechanisms of Cytidine AnaloguesLiewei Wang; Fiscal Year: 2010....